Ilanit Shalom-Sharabi1,2, Noah Samuels1,3, Efraim Lev4, Ofer Lavie5, Lital Keinan-Boker6,7, Elad Schiff8, Eran Ben-Arye9,10. 1. Integrative Oncology Program, The Oncology Service, Lin Medical Center, Clalit Health Services, 35 Rothschild St., Haifa and Western Galilee District, Israel. 2. Graduate Studies Authority, Haifa University, Haifa, Israel. 3. Tal Center for Integrative Medicine, Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel. 4. Department of Israel Studies, University of Haifa, Haifa, Israel. 5. Department of Obstetrics and Gynecology, Gynecologic Oncology Service, Carmel Medical Center, Haifa, Israel. 6. School of Public Health, Faculty of Social Welfare & Health Sciences, University of Haifa, Haifa, Israel. 7. Israel Center for Disease Control, Israel Ministry of Health, Jerusalem, Israel. 8. Department of Internal Medicine and Integrative Medicine Service, Bnai-Zion Hospital, Haifa, Israel. 9. Integrative Oncology Program, The Oncology Service, Lin Medical Center, Clalit Health Services, 35 Rothschild St., Haifa and Western Galilee District, Israel. eranben@netvision.net.il. 10. Complementary and Traditional Medicine Unit, Department of Family Medicine, Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. eranben@netvision.net.il.
Abstract
OBJECTIVE: Despite the growing evidence supporting the use of complementary/integrative medicine (CIM) in the treatment of chemotherapy-induced toxicities, little is known on CIM impact of these therapies regarding the use of medications for supportive cancer care. In this study, we examined the impact of CIM on the need for supportive cancer care-related medications. PATIENTS AND METHODS: Patients with breast or gynecological cancer referred to and attending an integrative physician (IP) consultation for gastrointestinal (GI) concerns were designated as the treatment group; those not attending as controls. Adherence to the integrative care program (AIC) was defined as attending ≥4 CIM interventions. The need for conventional supportive care-related medications and doses was determined from patients' medical files, as well as the implications on the potential for cost reduction. RESULTS: Of the 205 patients diagnosed with GI concerns, 116 attended the IP consultation and weekly CIM treatments (56.6%; treatment group), of which 85 (73.3%) were adherent to the program (AIC subgroup); 89 did not undergo an IP consultation (43.4%; controls). Within-group analysis found a greater decrease in the use of non-opioid analgesics (NOAs) at 6 weeks in the treatment group (P = 0.01), more so in the AIC subgroup (P = 0.02). A cost analysis suggests that reduced NOA use in the treatment group reduced the cost of supportive care, covering 27.1% of the overall expense of CIM treatments. Controls were less likely to require anti-emetics (P = 0.007). Between-group analysis showed a trend for reduced use of anxiolytics (P = 0.06) and NOAs (P = 0.08) among treated patients, with lower dose equivalents for NOAs than controls (P < 0.001). CONCLUSION: CIM treatments may reduce the need for NOAs among patients with breast or gynecological cancer.
OBJECTIVE: Despite the growing evidence supporting the use of complementary/integrative medicine (CIM) in the treatment of chemotherapy-induced toxicities, little is known on CIM impact of these therapies regarding the use of medications for supportive cancer care. In this study, we examined the impact of CIM on the need for supportive cancer care-related medications. PATIENTS AND METHODS: Patients with breast or gynecological cancer referred to and attending an integrative physician (IP) consultation for gastrointestinal (GI) concerns were designated as the treatment group; those not attending as controls. Adherence to the integrative care program (AIC) was defined as attending ≥4 CIM interventions. The need for conventional supportive care-related medications and doses was determined from patients' medical files, as well as the implications on the potential for cost reduction. RESULTS: Of the 205 patients diagnosed with GI concerns, 116 attended the IP consultation and weekly CIM treatments (56.6%; treatment group), of which 85 (73.3%) were adherent to the program (AIC subgroup); 89 did not undergo an IP consultation (43.4%; controls). Within-group analysis found a greater decrease in the use of non-opioid analgesics (NOAs) at 6 weeks in the treatment group (P = 0.01), more so in the AIC subgroup (P = 0.02). A cost analysis suggests that reduced NOA use in the treatment group reduced the cost of supportive care, covering 27.1% of the overall expense of CIM treatments. Controls were less likely to require anti-emetics (P = 0.007). Between-group analysis showed a trend for reduced use of anxiolytics (P = 0.06) and NOAs (P = 0.08) among treated patients, with lower dose equivalents for NOAs than controls (P < 0.001). CONCLUSION:CIM treatments may reduce the need for NOAs among patients with breast or gynecological cancer.
Entities:
Keywords:
Chemotherapy; Complementary medicine; Integrative medicine; Medication use; Supportive care
Authors: Wendy H Oldenmenger; Pleun J de Raaf; Cora de Klerk; Carin C D van der Rijt Journal: J Pain Symptom Manage Date: 2012-09-25 Impact factor: 3.612
Authors: Jean S Kutner; Marlaine C Smith; Lisa Corbin; Linnea Hemphill; Kathryn Benton; B Karen Mellis; Brenda Beaty; Sue Felton; Traci E Yamashita; Lucinda L Bryant; Diane L Fairclough Journal: Ann Intern Med Date: 2008-09-16 Impact factor: 25.391
Authors: Ilanit Shalom Sharabi; Anna Levin; Elad Schiff; Noah Samuels; Olga Agour; Yehudith Tapiro; Efraim Lev; Lital Keinan-Boker; Eran Ben-Arye Journal: Support Care Cancer Date: 2016-05-11 Impact factor: 3.603
Authors: Chao Hsing Yeh; Lung-Chang Chien; Wei-Chun Lin; Dana Howard Bovbjerg; G J van Londen Journal: Cancer Nurs Date: 2016 Sep-Oct Impact factor: 2.592
Authors: David G Pfister; Barrie R Cassileth; Gary E Deng; K Simon Yeung; Jennifer S Lee; Donald Garrity; Angel Cronin; Nancy Lee; Dennis Kraus; Ashok R Shaha; Jatin Shah; Andrew J Vickers Journal: J Clin Oncol Date: 2010-04-20 Impact factor: 44.544
Authors: Jun J Mao; Sharon X Xie; John T Farrar; Carrie T Stricker; Marjorie A Bowman; Deborah Bruner; Angela DeMichele Journal: Eur J Cancer Date: 2013-10-24 Impact factor: 9.162
Authors: Lisette Binkhorst; Ron H J Mathijssen; Myrthe P P van Herk-Sukel; Marjolein Bannink; Agnes Jager; Erik A C Wiemer; Teun van Gelder Journal: Breast Cancer Res Treat Date: 2013-06-13 Impact factor: 4.872
Authors: Jan Valentini; Daniela Fröhlich; Regina Stolz; Cornelia Mahler; Peter Martus; Nadja Klafke; Markus Horneber; Jona Frasch; Klaus Kramer; Hartmut Bertz; Barbara Grün; Katrin Tomaschko-Ubeländer; Stefanie Joos Journal: BMJ Open Date: 2022-02-11 Impact factor: 2.692